Lactam bridge is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
== Medical uses == Posaconazole is used to treat invasive Aspergillus and Candida infections. It is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to other drugs such as itraconazole and fluconazole. Clinical evidence of efficacy in treatment of invasive disease caused by Fusarium species (fusariosis) is limited. Intravenous administration appears to be helpful in a mouse model of naegleriasis and the drug kills Acanthamoeba castellanii cysts in vitro. It has been used to treat mucormycosis (black fungus disease) caused by Rhizopus mold.
6 April – Jim McKeever, 92, Gaelic footballer (Ballymaguigan, Newbridge, Derry senior team, Ulster). Born in Northern Ireland. 10 April John Joe Walsh, 82, Gaelic footballer (St Laurence's, Kildare senior team) and selector (Kildare). Pat Magner, 82, politician, Senator (1982–1982, 1983–1987 and 1993–1997). 12 April – Senan Louis O'Donnell, 96, Roman Catholic prelate, bishop of Maiduguri (1993–2003). 13 April – Craig Breen, 33, rally driver, car crash. 14 April – Mark Sheehan, 46, singer-songwriter, guitarist and producer. 18 April – Colm Murphy, 70, Irish republican and convicted arms trafficker (Omagh bombing), degenerative lung disease. 22 April Mick Loftus, 93, Gaelic footballer (Mayo senior team), referee and GAA president. Hugh Byrne, 83, politician, TD (1969–1982). 28 April – Johnny Fean, 71, guitarist (Horslips).
New methods for tracking biomolecules have been developed including the use of colorimetric biosensors, photochromic compounds, biomaterials, and electrochemical sensors. Fluorescent labeling is also a common method in which applications have expanded to enzymatic labeling, chemical labeling, protein labeling, and genetic labeling.
The Archbishop of Canterbury, Justin Welby, announces his resignation following a review of his handling of historical allegations of abuse in the church by the barrister John Smyth QC. The NHS is to start offering Varenicline, a daily pill to help people stop smoking. A man is arrested in Westminster after reports of someone carrying a knife outside the Houses of Parliament. Samantha Harvey wins the Booker Prize for her novel Orbital. 13 November The Guardian announces that all 80 of its accounts on social media platform X (formerly Twitter) will stop posting content, due to the social media site's role in spreading far-right conspiracy theories and racism. DIY retailer Homebase collapses into administration, threatening 2,000 jobs. Statistics have revealed that a 26-year-old man from Wales is one of around 50 motorists still allowed to drive, despite exceeding the 30 penalty point limit, having accrued 229 penalty points. Health Secretary Wes Streeting orders a review into the potential cost to the NHS of implementing changes to the law regarding assisted dying. Streeting unveils plans for hospital league tables, and for the managers of failing hospitals to be sacked. 14 November Chancellor Rachel Reeves is reported to be planning the "biggest pension reform in decades" by merging council pension schemes into "pension megafunds" hoping they will boost economic growth. Three women who were employees of Harrods allege that they were sexually abused by Mohamed Al-Fayed's brother, Salah between 1989 and 1997.
== Modern experimental pathology == As new research techniques, such as electron microscopy, immunohistochemistry, and molecular biology have expanded the means by which biomedical scientists can study disease, the definition and boundaries of investigative pathology have become less distinct. In the broadest sense, nearly all research which links manifestations of disease to identifiable processes in cells, tissues, or organs can be considered experimental pathology.
Sources: en.wikipedia.org
=== Eugenics === Crick occasionally expressed his views on eugenics, usually in private letters. For example, Crick advocated a form of positive eugenics in which wealthy parents would be encouraged to have more children. He once remarked, "In the long run, it is unavoidable that society will begin to worry about the character of the next generation ... It is not a subject at the moment which we can tackle easily because people have so many religious beliefs and until we have a more uniform view of ourselves I think it would be risky to try and do anything in the way of eugenics ... I would be astonished if, in the next 100 or 200 years, society did not come round to the view that they would have to try to improve the next generation in some extent or one way or another."
== Side effects == Common side effects of the ixazomib+lenalidomide+dexamethasone study therapy included diarrhea (42% versus 36% under placebo+lenalidomide+dexamethasone), constipation (34% versus 25%), thrombocytopenia (low platelet count; 28% versus 14%), peripheral neuropathy (28% versus 21%), nausea (26% versus 21%), peripheral oedema (swelling; 25% versus 18%), vomiting (22% versus 11%), and back pain (21% versus 16%). Serious diarrhoea or thrombocytopenia occurred in 2% of patients, respectively. Side effects of ixazomib alone were only assessed in a small number of people. Diarrhea grade 2 or higher was found in 24% of these patients, thrombocytopenia grade 3 or higher in 28%, and fatigue grade 2 or higher in 26%.
Portal was initially released in October 2007 as part of a compilation game called The Orange Box, alongside Half-Life 2 and its two episodes and Team Fortress 2. Valve considered including Portal as a bonus feature of the compilation; the game was purposely kept short such that if it did not meet expectations, players would have the rest of the content of The Orange Box as a "safety net". Portal has since been repackaged on Windows as a standalone game in April 2008. A Mac OS X client was introduced simultaneously with the release of the Steam client for that platform in May 2010; as part of its promotion, the game was released free of charge for both platforms during which at least 1.5 million players downloaded it.
== Hepatic Impairment == No dose adjustment is required, as hepatic metabolism does not significantly affect the drug's pharmacokinetics. Trelagliptin is not significantly metabolized by the liver, so hepatic function has minimal impact on its pharmacokinetics and most of the drug is excreted unchanged in urine.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.